Merck & Co. Inc.

09/18/2021 | Press release | Distributed by Public on 09/18/2021 07:17

Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant[...]